Search clinical trials for: JNJ-31001074

Total 872 results

Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Urologic Diseases | Urinary Bladder Diseases | Cystitis | Cystitis, Interstitial

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Pain | Osteoarthritis | Joint Pain | Arthralgia | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Canada, Korea, Republic of
Janssen Sciences Ireland UC

Terminated

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Virus Diseases | Respiratory Syncytial Virus Infections

Australia, Spain, Belgium, Sweden, Netherlands, Brazil, Germany, Argentina, Philippines, United States
Janssen Research & Development, LLC

Completed

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous

France, United Kingdom, Spain, Portugal, United States, Germany
Zujiang YU

Not yet recruiting

Prevention of Cancer Development and Progression

Cancer
Aragon Pharmaceuticals, Inc.

Completed

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom, Moldova, Republic of
Janssen Research & Development, LLC

Completed

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Multiple Myeloma

Japan
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Plaque Psoriasis

United States, Korea, Republic of, Taiwan, Germany, Poland, Brazil, Spain, Hungary, Australia, Canada, Romania
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

Multiple Myeloma

China
Janssen Research & Development, LLC

Completed

A Study of JNJ-61393215 in the Treatment of Depression

Major Depressive Disorder With Anxious Distress

United States, Moldova, Republic of, Russian Federation, Ukraine, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain

Alzheimer Disease

Belgium
Janssen Research & Development, LLC

Completed

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Pain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, Splitting

United States, France, Spain, Poland, Portugal
Lung Cancer Group Cologne

Terminated

FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)

NSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary Neoplasm

Germany
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Multiple Myeloma

China
Rabin Medical Center
Janssen, LP

Recruiting

Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

Central Nervous System Lymphoma

Israel
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

Focal Onset Seizures

Germany, Korea, Republic of, Belgium, United States, Russian Federation, Poland, Ukraine, Spain
CCTU- Cancer Theme
Janssen-Cilag Ltd.

Completed

Therapeutics in Active Prostate Cancer Surveillance (TAPS01)

Prostate Cancer

United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Research & Development, LLC

Completed

A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants

Healthy

Belgium
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older (Engage)

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

United States, Poland, Belgium, Canada
Actelion

Terminated

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag (SPHINX)

Sarcoidosis-associated Pulmonary Hypertension

United States, Germany, Canada, United Kingdom, Belgium, France, Netherlands, Italy, Brazil, Spain
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants

Healthy

Belgium, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

Healthy

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Korea, Republic of, United States, Brazil, Japan, Spain, Argentina, Hungary, Poland, United Kingdom, Australia, Taiwan, Canada, Germany
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER (BALANCE)

PSA Progression | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States, Canada
Royal Marsden NHS Foundation Trust
Janssen, LP

Unknown

Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma (iMYC)

Gastrooesophageal Cancer

United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

Urinary Bladder Neoplasms

Taiwan, Korea, Republic of, Austria, Germany, China, United States, Greece, Italy, Argentina, Belgium, Brazil, Russian Federation, Spain, Canada, Czechia, France, Mexico, Japan, Poland, Portugal, Australia, Hungary, Turkey, India, Ukraine
Actelion

Active, not recruiting

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Belgium, Taiwan, Israel, United States, France, China, United Kingdom, Malaysia, Belarus, Canada, Germany, Hungary, Russian Federation, Serbia, Ukraine, Poland
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Czechia, Israel, Italy, Korea, Republic of, Brazil, United Kingdom, Japan, Taiwan, Australia, Poland, Spain, France, Russian Federation, Sweden, Ukraine, Greece
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
National Cancer Institute (NCI)

Not yet recruiting

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
Janssen Research & Development, LLC

Terminated

A Single and Multiple Ascending Dose Study of JNJ-64457744

Healthy | Hepatitis B, Chronic

New Zealand
Furiex Pharmaceuticals, Inc

Completed

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

Complicated Skin and Skin Structure Infections

United States
Actelion

Recruiting

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (PLATYPUS)

Hypertension, Pulmonary

Korea, Republic of, Taiwan, Poland, Bulgaria, Ukraine, Belgium, South Africa, Belarus, Russian Federation
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

COVID-19 Prevention

United States, Belgium, Poland
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Adenocarcinoma | Prostatic Neoplasms

United States
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (YATAGARASU)

Salivary Gland Neoplasms

Japan
Janssen Research & Development, LLC

Completed

Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants

Healthy Participants

Belgium
Janssen R&D Ireland

Terminated

Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382

Chronic Hepatitis C Infection

Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis (FRONTIER 1)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Canada, Japan, Taiwan, Spain, United Kingdom, Poland
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 and Digoxin in Healthy Participants

Healthy

Belgium

Search clinical trials for: JNJ-31001074

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations